Has nature already identified all useful antibacterial targets?

Current Opinion in Microbiology

Volumn 11, Issue 5, 2008, Pages 387-392

  Bumann, Dirk ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

16S RIBOSOME RNA; 23S RIBOSOME RNA; ALANINE RACEMASE; ANTIBACTERIAL TARGET PROTEIN; ANTIBIOTIC AGENT; BACITRACIN; BACTERIAL ENZYME; BETA LACTAM ANTIBIOTIC; CYCLOSERINE; DELTA9 STEAROYL DESATURASE; DEXTRO ALANINE DEXTRO ALANINE LIGASE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; DNA GYRASE COMPLEX; DNA TOPOISOMERASE COMPLEX; FOSFOMYCIN; GAMMA GLUTAMYLTRANSFERASE; GYRASE; ISOLEUCINE TRANSFER RNA; LIPID; NOVOBIOCIN; PROTEIN; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; RIFAMPICIN; RNA POLYMERASE; UNCLASSIFIED DRUG; UNDECAPRENYL PYROPHOSPHATE LIPID CARRIER; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; COMPUTER MODEL; DRUG RESEARCH; DRUG TARGETING; GENETIC CONSERVATION; NONHUMAN; PROTEIN TARGETING; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS;

BACTERIA (MICROORGANISMS);

EID: 55049136420     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2008.08.002     Document Type: Review

References (27)

1. Norrby S.R., Nord C.E., and Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis 5 (2005) 115-119
2. Projan S.J., and Bradford P.A. Late stage antibacterial drugs in the clinical pipeline. Curr Opin Microbiol 10 (2007) 441-446
3. Spellberg B., Powers J.H., Brass E.P., Miller L.G., and Edwards Jr. J.E. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38 (2004) 1279-1286
4. Payne D.J., Gwynn M.N., Holmes D.J., and Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6 (2007) 29-40. Comprehensive review of difficulties in antimicrobial R&D from an industrial perspective.
5. Lange R.P., Locher H.H., Wyss P.C., and Then R.L. The targets of currently used antibacterial agents: lessons for drug discovery. Curr Pharm Des 13 (2007) 3140-3154. Detailed analysis of targets of currently used antibiotics. Interestingly, most antibiotics appear to interact with multiple, often unrelated targets.
6. Baba T., Ara T., Hasegawa M., Takai Y., Okumura Y., Baba M., Datsenko K.A., Tomita M., Wanner B.L., and Mori H. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol 2 (2006) 2006.0008. This publication defines the set of essential in the prime model microbe Escherichia coli under two experimental conditions. Comparison with other bacteria revealed only 42 essential and broadly conserved genes.
7. Black M.T., and Hodgson J. Novel target sites in bacteria for overcoming antibiotic resistance. Adv Drug Deliv Rev 57 (2005) 1528-1538
8. Baltz R.H. Renaissance in antibacterial discovery from actinomycetes. Curr Opin Pharmacol 3 (2008) 3. Overview of challenges and opportunities for discovering natural products with novel antimicrobial mechanisms.
9. Poehlsgaard J., and Douthwaite S. The bacterial ribosome as a target for antibiotics. Nat Rev Microbiol 3 (2005) 870-881
10. Wyss P.C., Gerber P., Hartman P.G., Hubschwerlen C., Locher H., Marty H.P., and Stahl M. Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening. J Med Chem 46 (2003) 2304-2312
11. Loferer H. Mining bacterial genomes for antimicrobial targets. Mol Med Today 6 (2000) 470-474
12. Hillenmeyer M.E., Fung E., Wildenhain J., Pierce S.E., Hoon S., Lee W., Proctor M., St Onge R.P., Tyers M., Koller D., et al. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320 (2008) 362-365
13. Muzzi A., Masignani V., and Rappuoli R. The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials. Drug Discov Today 12 (2007) 429-439. Genetic diversity of pathogen clinical isolates complicates the development of control strategies. Comprehensive analysis of the corresponding 'pan-genome' could provide a more reliable picture of gene essentiality.
14. Kobayashi K., Ehrlich S.D., Albertini A., Amati G., Andersen K.K., Arnaud M., Asai K., Ashikaga S., Aymerich S., Bessieres P., et al. Essential Bacillus subtilis genes. Proc Natl Acad Sci U S A 100 (2003) 4678-4683
15. Thomson C.J., Power E., Ruebsamen-Waigmann H., and Labischinski H. Antibacterial research and development in the 21(st) Century - an industry perspective of the challenges. Curr Opin Microbiol 7 (2004) 445-450
16. Moy T.I., Ball A.R., Anklesaria Z., Casadei G., Lewis K., and Ausubel F.M. Identification of novel antimicrobials using a live-animal infection model. Proc Natl Acad Sci U S A 103 (2006) 10414-10419. Screening approach utilizing an invertebrate model host. The data suggest more stringent requirements in infected host animals compared to in vitro cultures.
17. Mazurkiewicz P., Tang C.M., Boone C., and Holden D.W. Signature-tagged mutagenesis: barcoding mutants for genome-wide screens. Nat Rev Genet 7 (2006) 929-939
18. Muschiol S., Bailey L., Gylfe A., Sundin C., Hultenby K., Bergstrom S., Elofsson M., Wolf-Watz H., Normark S., and Henriques-Normark B. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc Natl Acad Sci U S A 103 (2006) 14566-14571
19. Cegelski L., Marshall G.R., Eldridge G.R., and Hultgren S.J. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 6 (2008) 17-27
20. Smith E.E., Buckley D.G., Wu Z., Saenphimmachak C., Hoffman L.R., D'Argenio D.A., Miller S.I., Ramsey B.W., Speert D.P., Moskowitz S.M., et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 103 (2006) 8487-8492
21. Becker D., Selbach M., Rollenhagen C., Ballmaier M., Meyer T.F., Mann M., and Bumann D. Robust Salmonella metabolism limits possibilities for new antimicrobials. Nature 440 (2006) 303-307. Extensive in vivo screen of metabolic targets in a Gram-negative pathogen. The data suggest unexpected rich host microenvironments even for this intracellular pathogen as one primary reason for the small number of suitable targets.
22. Schmid M.B. Do targets limit antibiotic discovery?. Nat Biotechnol 24 (2006) 419-420. Questions some of the selection criteria for targets in the preceding study and stresses the fact that a few targets might be actually sufficient for developing clinically useful antimicrobials.
23. Cole S.T., Eiglmeier K., Parkhill J., James K.D., Thomson N.R., Wheeler P.R., Honore N., Garnier T., Churcher C., Harris D., et al. Massive gene decay in the leprosy bacillus. Nature 409 (2001) 1007-1011
24. Glass J.I., Assad-Garcia N., Alperovich N., Yooseph S., Lewis M.R., Maruf M., Hutchison III C.A., Smith H.O., and Venter J.C. Essential genes of a minimal bacterium. Proc Natl Acad Sci U S A 103 (2006) 425-430. Exhaustive analysis of gene essentiality in the pathogen with the smallest genome.
25. Frantz S. Drug discovery: playing dirty. Nature 437 (2005) 942-943
26. Buynak J.D. Understanding the longevity of the beta-lactam antibiotics and of antibiotic/beta-lactamase inhibitor combinations. Biochem Pharmacol 71 (2006) 930-940
27. Becker S.A., Feist A.M., Mo M.L., Hannum G., Palsson B.O., and Herrgard M.J. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox. Nat Protoc 2 (2007) 727-738. Open-source tools for computational prediction of essential genes and synthetically lethal defects.